Literature DB >> 15898733

Radioiodinated azide and isothiocyanate derivatives of cocaine for irreversible labeling of dopamine transporters: synthesis and covalent binding studies.

John R Lever1, Mu-Fa Zou, M Laura Parnas, Romain A Duval, Sara E Wirtz, Joseph B Justice, Roxanne A Vaughan, Amy Hauck Newman.   

Abstract

Two novel N-substituted-3beta-phenyltropane alkaloids have been labeled with iodine-125 for use as irreversible probes of dopamine transporter (DAT) binding sites. One contains an iodoaryl azide moiety for photolabeling, while the other bears an iodoaryl isothiocyanate for direct conjugation. Both radioligands were prepared in a one-flask procedure by electrophilic radioiodination of the corresponding aniline under no-carrier-added conditions, followed either by diazotization and treatment with sodium azide, or by addition of thiophosgene under basic conditions. Specifically, (-)-N-[4-(3-[(125)I]iodo-4-azidophenyl)butyl]-2beta-carbomethoxy-3beta-(4-chlorophenyl)tropane ([(125)I]MFZ-2-24) and (-)-N-[4-(3-[(125)I]iodo-4-isothiocyanophenyl)butyl]-2beta-carbomethoxy-3beta-(4-chlorophenyl)tropane ([(125)I]MFZ 3-37) were synthesized. Isolation by reversed-phase HPLC and solid-phase extraction gave good average yields of [(125)I]MFZ-2-24 (67%, n = 5) and [(125)I]MFZ-3-37 (45%, n = 3) with high radiochemical purities (96-99%) and specific radioactivities (>2000 mCi/micromol). The utility of the radioligands was demonstrated by their covalent linkage to rat striatal membranes, and immunoprecipitation of a single radiolabeled band at 80 kDa corresponding to the full-length DAT.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15898733     DOI: 10.1021/bc0497214

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  6 in total

Review 1.  Recognition of psychostimulants, antidepressants, and other inhibitors of synaptic neurotransmitter uptake by the plasma membrane monoamine transporters.

Authors:  Christopher K Surratt; Okechukwu T Ukairo; Suneetha Ramanujapuram
Journal:  AAPS J       Date:  2005-10-27       Impact factor: 4.009

2.  Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.

Authors:  David J Lapinsky; Ranganadh Velagaleti; Nageswari Yarravarapu; Yi Liu; Yurong Huang; Christopher K Surratt; John R Lever; James D Foster; Rejwi Acharya; Roxanne A Vaughan; Howard M Deutsch
Journal:  Bioorg Med Chem       Date:  2010-11-04       Impact factor: 3.641

3.  (±)-2-(N-tert-Butylamino)-3'-[(125)I]-iodo-4'-azidopropiophenone: a dopamine transporter and nicotinic acetylcholine receptor photoaffinity ligand based on bupropion (Wellbutrin, Zyban).

Authors:  David J Lapinsky; Shaili Aggarwal; Tammy L Nolan; Christopher K Surratt; John R Lever; Rejwi Acharya; Roxanne A Vaughan; Akash Pandhare; Michael P Blanton
Journal:  Bioorg Med Chem Lett       Date:  2011-11-04       Impact factor: 2.823

4.  A novel photoaffinity ligand for the dopamine transporter based on pyrovalerone.

Authors:  David J Lapinsky; Shaili Aggarwal; Yurong Huang; Christopher K Surratt; John R Lever; James D Foster; Roxanne A Vaughan
Journal:  Bioorg Med Chem       Date:  2009-05-03       Impact factor: 3.641

5.  Evolution of a Compact Photoprobe for the Dopamine Transporter Based on (±)-threo-Methylphenidate.

Authors:  David J Lapinsky; Nageswari Yarravarapu; Tammy L Nolan; Christopher K Surratt; John R Lever; Michael Tomlinson; Roxanne A Vaughan; Howard M Deutsch
Journal:  ACS Med Chem Lett       Date:  2012-03-11       Impact factor: 4.345

6.  Novel Azido-Iodo Photoaffinity Ligands for the Human Serotonin Transporter Based on the Selective Serotonin Reuptake Inhibitor (S)-Citalopram.

Authors:  Vivek Kumar; Nageswari Yarravarapu; David J Lapinsky; Danielle Perley; Bruce Felts; Michael J Tomlinson; Roxanne A Vaughan; L Keith Henry; John R Lever; Amy Hauck Newman
Journal:  J Med Chem       Date:  2015-07-08       Impact factor: 7.446

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.